Fierce Pharma3d
Zevra Therapeutics embarks on diagnosis push as Miplyffa launch gains steam
It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $22 from $20 and keeps a Buy rating on the shares. The Miplyffa ...
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00
Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 ...
Zevra Therapeutics price target raised to $25 from $23 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the ...
Houston Chronicle5d
Zevra Therapeutics: Q4 Earnings Snapshot
(AP) — Zevra Therapeutics ... Zacks Investment Research was for a loss of 39 cents per share. The specialty pharmaceutical company posted revenue of $12 million in the period, exceeding Street ...